Skip to main navigation Skip to search Skip to main content

Consensus: Challenges and opportunities

  • Thomas J. Ferro
  • , Claudia Cote
  • , Ronald J. DeBellis
  • , Sheila Goodnight-White
  • , Joel B. Karlinsky
  • , Todd A. Lee
  • , Marvin D. Lesser
  • , Douglas B. Schwartz
  • , Sanjay Sethi
  • , Donald P. Tashkin
  • Virginia Commonwealth University
  • VA Medical Center
  • Department of Veterans Affairs
  • Massachusetts College of Pharmacy and Health Sciences
  • Baylor College of Medicine
  • Boston University
  • Northwestern University
  • Icahn School of Medicine at Mount Sinai
  • University of California at Los Angeles

Research output: Contribution to journalReview articlepeer-review

Abstract

In light of the increasing prevalence of chronic obstructive pulmonary disease (COPD) and the associated morbidity and mortality, attention should be focused on prevention and treatment optimization. Physicians must remain proactive in recognizing patients at risk for COPD and encouraging lifestyle changes that may help prevent progression of disease. Once disease is present, pharmacologic treatment should begin. It is essential that such treatment be aggressive and aimed at reducing symptoms, slowing lung function decline, improving compliance, and improving quality of life.

Original languageEnglish
Pages (from-to)S22-S23
JournalClinical Pulmonary Medicine
Volume12
Issue number4 SUPPL.
DOIs
StatePublished - Jul 2005

Keywords

  • Chronic obstructive pulmonary disease
  • Compliance
  • Quality of life

Fingerprint

Dive into the research topics of 'Consensus: Challenges and opportunities'. Together they form a unique fingerprint.

Cite this